MWVC
NTLA icon

Morgens Waterfall Vintiadis & Co’s Intellia Therapeutics NTLA Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,000
Closed -$497K – 69
2017
Q3 		$497K Buy
+20,000
New +$377K 0.42% 42

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's NTLA Position: Q4 2017 in Review

Morgens Waterfall Vintiadis & Co sold out of Intellia Therapeutics (NTLA) in Q4 2017, closing a stake of 20,000 shares — an estimated $497K sold.

Morgens Waterfall Vintiadis & Co first reported a position in NTLA in Q3 2017 and held it in 1 quarter. The position peaked at $497K in Q3 2017. 112 funds tracked by Wall St. Rank hold NTLA as of Q4 2017.

  • Morgens Waterfall Vintiadis & Co reported no remaining Intellia Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 20,000 Intellia Therapeutics shares in Q4 2017, an estimated $497K.
  • Morgens Waterfall Vintiadis & Co first reported a position in Intellia Therapeutics in Q3 2017 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Intellia Therapeutics position peaked at $497K in Q3 2017.
  • 112 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2017.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q4 2017, filed 14 Feb 2018.